Petr Sramek
Co-Founder, Chairman and Managing, General Partner @ Longevitytech.fund
Prague, Czech Republic
Petr Sramek is a seed investor at Longevitytech.fund in Prague focused on Life Science and Biotechnology. Petr Sramek is the Managing Partner of Longevitytech.fund. He previously worked at World Business Angels Investment Forum as a WBAF Senator Czech Republic. Petr Sramek attended MBA, Manchester University.
- Total investments:
- 4
- Last investment:
- Lead investor:
- 100%
Last updated:
For AI agents: llms.txt
Industries Petr Sramek invests in
Stages Petr Sramek invests in
Countries Petr Sramek invests in
Contacts
| Type | Contact | Validation |
|---|---|---|
| Work email | ||
| Personal email | ||
| Work phone | ||
| Personal phone | ||
| Socials |
Investment Focus
Industry
- Life Science 2 (50%)
- Biotechnology 2 (50%)
- Pharmaceutical 2 (50%)
- FinTech 1 (25%)
- Finance 1 (25%)
Stage
- Seed 2 (50%)
- Pre-Seed 1 (25%)
Country
- Israel 1 (25%)
- Austria 1 (25%)
- United States 1 (25%)
Investments
| Company | Description | Round | Links |
|---|---|---|---|
|
Klothea Bio
|
Klothea Bio is a protein well known for its powerful anti-aging capabilities, such as tumor suppression, neuroprotection, and antioxidative actions. As people age, their klotho levels drop to harmful levels. The metabolic disease syndrome will be the focus of the first investigations, while later studies will try to extend therapeutic applicationsto cancer, Alzheimer's disease, obesity, and other age-related diseases. | Seed / Nov 25, 2024 | |
| Celeris Therapeutics is a deep learning company that uses innovative, computer-based methods to degrade undruggable targets. The platform Celeris One exploits the potential of degrader technologies with accurate predictions of biomolecular interactions and the expansion of chemical space.Celeris One uses methods such as Graph RepresentationLearning, Active Learning, Data Augmentation, and Generative Models to expand the chemical space and leverage sparse and heterogeneous data. This leads to the design of Heterobifunctional and Glue Degraders, as well as Small Molecules. | $471.5K / Pre-Seed / Mar 28, 2021 | ||
| Vesttoo is the world’s first marketplace for non-catastrophe insurance-based risk transfer and investments. Our proprietary AI-based technology facilitates risk transfer between insurance companies and institutional investors, providing insurance-linked investments to asset managers of all types, while enhancing risk transfer and liquidity in theLife and P&C insurance markets.Our platform facilitates risk transfer to the capital markets with a faster time to market, providing insurers with an affordable, accurate alternative or supplement to traditional reinsurance with unlimited capacity from the capital markets, while we offer asset managers a variety of risk remote, uncorrelated investment options that generate sustainable alpha from a catered variety of insurance and reinsurance premiums.We collaborate with leaders in the field to build alternative reinsurance transactions covering a variety of Life and P&C insurance risks in transparent, data-driven alternative reinsurance and retrocession deals - run-off or treaty, parametric or portfolio-specific, standalone or on top of existing reinsurance towers. Our proprietary AI-based Machine Learning models have been developed independently, accepted by regulators, and externally audited by leaders in the field. Vesttoo was selected to participate in IBM Alpha Zone, Citigroup Accelerator, Plug and Play and Fintech Innovation Lab – all prestigious fintech accelerators, and most recently NVIDIA's inception program. Our management team has a diversified professional experience in global business development, investments, technology/systems/algorithms, financial engineering, reinsurance, credit rating and managementAdditional team members include: data scientists, financial engineers, actuaries, product managers, project managers, business development, strategy and marketing professionals. | Seed / Dec 20, 2020 | ||
| Vesttoo is the world’s first marketplace for non-catastrophe insurance-based risk transfer and investments. Our proprietary AI-based technology facilitates risk transfer between insurance companies and institutional investors, providing insurance-linked investments to asset managers of all types, while enhancing risk transfer and liquidity in theLife and P&C insurance markets.Our platform facilitates risk transfer to the capital markets with a faster time to market, providing insurers with an affordable, accurate alternative or supplement to traditional reinsurance with unlimited capacity from the capital markets, while we offer asset managers a variety of risk remote, uncorrelated investment options that generate sustainable alpha from a catered variety of insurance and reinsurance premiums.We collaborate with leaders in the field to build alternative reinsurance transactions covering a variety of Life and P&C insurance risks in transparent, data-driven alternative reinsurance and retrocession deals - run-off or treaty, parametric or portfolio-specific, standalone or on top of existing reinsurance towers. Our proprietary AI-based Machine Learning models have been developed independently, accepted by regulators, and externally audited by leaders in the field. Vesttoo was selected to participate in IBM Alpha Zone, Citigroup Accelerator, Plug and Play and Fintech Innovation Lab – all prestigious fintech accelerators, and most recently NVIDIA's inception program. Our management team has a diversified professional experience in global business development, investments, technology/systems/algorithms, financial engineering, reinsurance, credit rating and managementAdditional team members include: data scientists, financial engineers, actuaries, product managers, project managers, business development, strategy and marketing professionals. | Seed / Jul 02, 2020 |
Co-Investors
About Longevitytech.fund
Longevitytech.fund do pre-seed and seed-stage investments in the best of worldwide early-stage startups and spinoffs based on our close cooperation with top scientists in the field of aging research and rejuvenation, biotechnology, bioinformatics, agetech, and related AI. We Provide an active approach with entrepreneurial help, network andcommercialization support. We also provide longevity program for our LPs.
Longevitytech.fund Contacts
| Name | Phone | Socials | |
|---|---|---|---|
|
Petr Sramek
Co-Founder, Chairman and Managing, General Partner
|
|||
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Recommended lists
FAQ
What does Petr Sramek invest in?
Petr Sramek invests primarily in Life Science, Biotechnology and Pharmaceutical startups, most often at Seed and Pre-Seed stage. Most of the 4 investments tracked by Shizune back companies in Israel. The Investment Focus section breaks down every industry, stage and country in the portfolio.
How do I contact Petr Sramek?
Public channels for Petr Sramek include LinkedIn. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.
When did Petr Sramek last invest?
The most recent investment recorded for Petr Sramek closed in Nov 2024. Shizune tracks 4 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Oct 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
